ESPE Abstracts (2022) 95 P1-200

ESPE2022 Poster Category 1 Thyroid (44 abstracts)

Severe and Non Severe Forms of Autoimmune Hypothyroidism in Childhood: A Retrospective Analysis of 256 Cases

Giulio Maltoni 1 , Gaia Vincenzi 2 , Andrea Scozzarella 1 , Giulia Tarantola 2 , Maria Cristina Vigone 2 & Alessandra Cassio 1


1Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2Pediatric Unit, IRCCS Ospedale San Raffaele, Milano, Italy

Introduction: Hashimoto’s thyroiditis (HT) is one of the most common autoimmune diseases in childhood. Despite its frequency, there are still controversies concerning the spontaneous evolution and presentation in childhood. Aim and methods: this is a retrospective study aiming to evaluate clinical and hormonal features at diagnosis and auxological parameters after 3 years in subjects with Severe Autoimmune Hypothyroidism (SAH). We defined severe hypothyroidism as fT4 <5.5 pg/ml and TSH >30 mU/ml. Subjects’ characteristics with SAH (group A) were compared to those with HT subdivided in group B if TSH 10-30 mU/ml and fT4 normal or fT4 <5.5 pg/ml, group C if TSH 4,5-10 mU/l and fT4 normal and group D if TSH <4,5 mU/l and fT4 normal. Results: Mean features were reported in table.

Group (n.cases) Group A (n.46) Group B (n.26) Group C (n.56) Group D (n.128)
Mena Age at diagnosis (yrs±sds) 8,8±3,6* 10.46±3.0 11.36±2.6* 11.7±2.9*
Males (%) 21.7 34.6 33.9 21.1
Prepubertal stage (%) 63.4* 47.8 39.1 18.1*
TSH (mU/ml) 381.6±256.1* 16.1±6.6* 6.1±1.4* 3.0±1.0*
fT4 (Pg/ml) 3.1±1.6* 8.1±1.9* 8.7±1.6* 8.9±1.9*
Ab Anti-TPO (%) 95.6 92.3 87.5 72.6
Ab anti-Tireoglobulin (%) 80.5 76.9 75 63.3

In group A 58.7% referred symptoms of hypothyroidsm (Asthenia the most common, 40% in A, 11.5% in B, 5.3% in C and 4.7% in D, P<0.05 A vs B-C-D). In Group A 80% showed clinical signs as Goiter 51.9% in A, 19.2% in B, 17.8% in C and 12.5% in D, P<0.05 A vs B-C-D; Growth Delay 30.7% in A, 0% in B and C and 1.5% in D, P<0.05 A vs B-C-D. 72.9% of group A had a familiy history for autoimmune diseases, 59.9% for group B+C+D. At SAH diagnosis, group A presented a difference between Height and Target Height of -1.21 SDS (0.04 for group B+C+D), -0.92 after 2 years (66.6% of subjects) (0.01 for group B+C+D) and -0.68 after 3 years (80% of subjects) (0.01 for group B+C+D). Conclusions: The risk of developing SAH is greater in younger and prepubertal children, and they are more symptomatic. Family history for autoimmune diseases seems to be greater in subjects with SHA (Pediatricians should be aware of it and follow carefully screening programs). We detected growth impairment at diagnosis in SAH compared to HT, progressively improving.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.